Valeant Pharmaceuticals news from FierceBiotech
NewsValeant buys Coria for $95M
Valeant is shelling out $95 million to acquire Coria Laboratories, a pharmaceutical company focused on dermatology products in the United States. Valeant will purchase all of the outstanding shares... Read more...
GSK, Valeant ink $820M epilepsy deal
Valeant Pharmaceuticals will pocket a $125 million upfront fee from GlaxoSmithKline in exchange for a collaboration deal on the epilepsy drug
Valeant chops workforce in restructuring
In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. In addition, headcount will be further reduced by 1,250 positions as it divests its... Read more...
ALSO NOTED: Promacta gets priority review; GTx drug hits endpoint; Alexza touts IIa data; and much more...
> Glaxo's Promacta, a bleeding disorder drug, will be given a priority review by the FDA.
ALSO NOTED: Amgen analysts bearish; FDA hands Kyowa not-approvable letter; Valeant plans review; and much more...
> Oh, the curse of duplication. Schering-Plough embarked on a company-wide downsizing yesterday, eliminating hundreds of jobs in nearly all departments, including finance, research, information... Read more...
ALSO NOTED: Galenica share surge on committee approval; Progen to acquire CellGate; and much more...
> Shares of Galenica jumped 15 percent this morning after the company announced that an FDA advisory committee has endorsed its iron replacement therapy Ferinject/Injectafer. A formal decision is... Read more...
ALSO NOTED: Genitope's MyVax misses Phase III endpoint; Report: Pfizer looks at Danish biotechs; and much more...
> Genitope's MyVax, a treatment for follicular B-cell non-Hodgkin's lymphoma, has flunked a Phase III trial. There was no difference in progression-free survival between patients taking the drug... Read more...
ALSO NOTED: ReNeuron confident of trial OK; Valeant licenses Xyrem rights;and much more...> ReNeuron Group says it is confident that it can gain regulatory approval to start a Phase I stem cell trial of ReN001 after the FDA put a hold on the study on Tuesday. Report > Valeant Pharmaceuticals has licensed the Canadian rights to Jazz's cataplexy treatment Xyrem. Report > A group of … ... Read more...SPOTLIGHT: Valeant sells development programs
Schering-Plough licenses hepatitis B drugShares of Valeant Pharmaceuticals and Metabasis Technologies jumped late Wednesday after they announced that Schering-Plough had licensed the experimental pradefovir for chronic hepatitis B. Valeant licensed the drug from Metabasis six years ago. Both companies will earn an up-front payment along with a schedule of milestones. "Pradefovir has the potential to offer improved treatment options for patients with chronic hepatitis B, a serious blood-borne infection affecting some 400 … ... Read more... | Press ReleasesValeant Pharmaceuticals International (VRX) Signs Agreement to Acquire Coria Laboratories, Ltd. for $95 MillionValeant Pharmaceuticals International (VRX) Signs Agreement to Acquire Coria Laboratories, Ltd. for $95 Million ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX - News) today Read more >> GlaxoSmithKline and Valeant Pharmaceuticals Announce Worldwide Collaboration Agreement for RetigabineGlaxoSmithKline and Valeant Pharmaceuticals Announce Worldwide Collaboration Agreement for Retigabine LONDON, & ALISO VIEJO, California, Aug. 28, 2008-GlaxoSmithKline (GSK) and Valeant Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
